Celldex Therapeutics Inc Dossier - Source-backed chat

Celldex Therapeutics Inc

CLDXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.89

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $32.18Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $2.5B

Enterprise Value $2.5B

Shares Outstanding 72.3M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Celldex Therapeutics is a high-conviction, clinical-stage biotechnology company whose valuation is anchored by its lead asset, barzolvolimab (an anti-KIT monoclonal antibody). Barzolvolimab has demonstrated best-in-disease potential in Phase 2 trials for chronic spontaneous urticaria (CSU) and inducible urticarias, showing rapid, deep, and durable complete responses that exceed historical benchmarks. With Phase 3 CSU enrollment completed six months ahead of schedule, the company is on track for a transformative topline data readout in Q4 2026. A successful $345 million follow-on offering in April 2026 has significantly de-risked the near-term financial profile, extending the cash runway through 2028 and fully funding commercialization preparations. While the company remains pre-revenue and unprofitable, the clinical superiority of its mast-cell-targeting platform offers substantial asymmetric upside.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets15 analysts · as of 18 Aug 2026

Low · most bearish analyst$38.00

Mean target$58.07

High · most bullish analyst$100.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$38.0015%

Phase 3 CSU topline data in Q4 2026 fail to replicate the strong efficacy seen in Phase 2, or reveal safety concerns such as severe neutropenia or high rates of hair color changes that limit patient compliance. The BLA submission is delayed or rejected by the FDA, requiring additional clinical trials. Consequently, the stock suffers a severe narrative compression, and the company is forced to burn through its remaining cash reserves without a clear path to commercialization, leading to highly dilutive future capital raises.

Base CaseCentral scenario

$58.0755%

Matches the consensus mean

Phase 3 CSU trials meet their primary endpoints with high statistical significance in Q4 2026, demonstrating competitive efficacy and safety compared to standard of care (Xolair) and emerging competitors (Novartis's remibrutinib). Celldex proceeds with an independent BLA submission in 2027, utilizing its robust cash runway (funded through 2028) to build out its US commercial infrastructure. Phase 2 readouts in inducible urticarias (ColdU and SD) and prurigo nodularis show positive signals, supporting pipeline expansion.

Bull CaseUpside scenario

$100.0030%

Phase 3 CSU trials (EMBARQ-CSU 1 and 2) deliver outstanding topline results in Q4 2026, confirming barzolvolimab's best-in-class efficacy (complete response rates >50%) and a clean safety profile with no unexpected neutropenia or severe adverse events. This triggers a rapid BLA submission in early 2027 and attracts a lucrative global co-development/commercialization partnership with a major pharmaceutical firm, yielding a substantial upfront milestone payment. Concurrently, Phase 2 readouts in prurigo nodularis and atopic dermatitis succeed, establishing barzolvolimab as a multi-billion-dollar pipeline-in-a-product.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated Mechanism of Action: Barzolvolimab targets the KIT receptor with high specificity, potently inhibiting mast cell survival and activity, which addresses the root cause of chronic urticarias rather than just managing symptoms.
Compelling Phase 2 Clinical Data: Prior mid-stage trials demonstrated rapid, profound, and durable complete urticaria control, with benefits lasting up to seven months off-treatment (Week 76 data presented at EAACI 2026).
De-risked Balance Sheet: The April 2026 public offering raised $345 million in gross proceeds, extending the company's cash runway through 2028 and removing near-term financing overhangs.
Accelerated Execution: Phase 3 CSU enrollment of 1,939 patients was completed six months ahead of schedule, highlighting strong investigator and patient demand and accelerating the timeline to market.

Key Investment Risks

Binary Clinical Trial Risk: The company's valuation is highly concentrated in barzolvolimab; any failure or safety signal in the upcoming Q4 2026 Phase 3 CSU readout would severely impact the stock.
Intense Competitive Landscape: Celldex faces competition from established blockbusters (Xolair, Dupixent) and advanced pipeline candidates from large pharmaceutical companies (Novartis's remibrutinib).
Pre-commercial Execution Risk: As a clinical-stage company with no current product revenues, Celldex must successfully transition to a commercial-stage organization, which involves high operational and marketing expenses.

Thesis Invalidation Triggers

Failure of EMBARQ-CSU Phase 3 trials to meet their primary efficacy endpoints in Q4 2026.
Emergence of serious safety concerns (e.g., severe, prolonged neutropenia or systemic toxicity) in Phase 3 trials.
FDA refusal to file or approve the BLA for barzolvolimab in 2027.
Significant delays in the clinical timelines for inducible urticaria (ColdU/SD) or prurigo nodularis programs.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.